Gilead Sciences Inc (GILD)

GILD (NASDAQ:Drugs) EQUITY
$102.01
neg -3.10
-2.90%
Today's Range: 101.77 - 104.64 | GILD Avg Daily Volume: 10,733,500
Last Update: 09/01/15 - 2:19 PM EDT
Volume: 7,452,819
YTD Performance: 11.47%
Open: $102.22
Previous Close: $105.07
52 Week Range: $85.95 - $123.37
Oustanding Shares: 1,467,605,502
Market Cap: 158,178,521,006
6-Month Chart
TheStreet Ratings Grade for GILD
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 11 11 11 10
Moderate Buy 3 3 3 3
Hold 1 1 1 2
Moderate Sell 1 1 1 1
Strong Sell 0 0 0 0
Mean Rec. 1.47 1.47 1.47 1.59
Latest Dividend: 0.43
Latest Dividend Yield: 1.60%
Dividend Ex-Date: 09/14/15
Price Earnings Ratio: 11.33
Price Earnings Comparisons:
GILD Sector Avg. S&P 500
11.33 11.30 25.39
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
-6.41% -2.32% 264.26%
GROWTH 12 Mo 3 Yr CAGR
Revenue 122.20 1.97 0.43
Net Income 294.40 3.32 0.62
EPS 305.00 3.39 0.63
Earnings for GILD:
EBITDA 16.32B
Revenue 24.89B
Average Earnings Estimates
Qtr (09/15) Qtr (12/15) FY (12/15) FY (12/16)
Average Estimate $3.03 $2.98 $11.99 $10.53
Number of Analysts 1 1 1 1
High Estimate $3.03 $2.98 $11.99 $10.53
Low Estimate $3.03 $2.98 $11.99 $10.53
Prior Year $1.79 $2.38 $7.91 $11.99
Growth Rate (Year over Year) 69.27% 25.21% 51.58% -12.18%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands
Which means interest rate hikes are being built into prices.
We saw this coming, but there's more to the recent turmoil than China.
Although itis never comfortable buying into a selloff, it will look very smart in 6 months.
It could be time to deploy some of your dry powder.
Bet on small-caps with big-name collaborators.
Still, momentum is cooling and valuation is an issue in more cases.
Drugmaker has one of the best showings of earnings season.
Drugmaker has one of the best showings of earnings season.

Sticking Up for the Ex-Im Bank Real Money Pro($)

Markets still are holding their gains as we come to midday. Interestingly, the biotech index is off today despite great results and a solid up day from Gilead Sciences (GILD), one of the four horsemen of biotech. Some infrastructure plays such as Mastec (MTZ) and Terex (TEX) are having nice days and are up 3% or so on the day.

Stocks Slightly Higher Real Money Pro($)

Stocks opened modestly higher this morning as investors digested various earnings reports, but the market has given up some of its early gains.

Columnist Conversations

Just an ugly, ugly day to begin the month as all major indices are down approximately 2.5%. Domestic economy ...
XIV is another example of why catching a falling enough can be so tough and the market gives no free lunches.
We did see sell triggers against the timing in SPX, now here is the next decision on the way down. If we brea...
"No post-Europe bounce in first thirty minutes. In fact, they initially trade as though they want to retest t...

REAL MONEY'S BEST IDEAS

News Breaks

Powered by

BROKERAGE PARTNERS

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.